H. Rhodius-Meester, I. van Maurik, J. Koikkalainen, A. Tolonen, K. Frederiksen, S. Hasselbalch, H. Soininen, S-K. Herukka, A. Remes, C. Teunissen, F. Barkhof, Y. Pijnenburg, P. Scheltens, J. Lötjönen, W. van der Flier
Alzheimer’s disease diagnostic criteria allow the use of CSF biomarkers to support diagnosis, but tools are needed to help select patients for which CSF biomarkers have clinical utility. In this study, a computerized decision support system to select patients for CSF biomarkers was evaluated. Simulated CSF biomarkers, in combination with demographic, neuropsychology, and MRI data, in control participants, Alzheimer’s disease dementia, frontotemporal dementia, and vascular dementia were used to estimate the impact on the confidence in diagnosis. The computer-supported prediction restricted CSF testing to only 26% of cases, without compromising diagnostic accuracy.